{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-091482","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.350825+00:00","generated_at":"2026-05-15T21:40:41.967233+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M","bullets":["Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.","Q4 net loss $4.2M ($0.08 loss per share) vs $11.8M loss in Q4 2024; full-year net loss $38.4M vs $51.5M.","Cash $92M at Dec 31, 2025; Q4 cash used only $0.4M; full-year cash used $28.4M.","FY 2026 guidance: revenue $82-88M (+6-14% YoY); Glaucoma $77-81M; Dry Eye $5-7M.","Operating expenses down 25% Q4 and 13% full-year; adjusted op ex guidance $93-96M for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-091482","json":"https://secwatch.observer/filing/0001193125-26-091482.json","markdown":"https://secwatch.observer/filing/0001193125-26-091482.md","text":"https://secwatch.observer/filing/0001193125-26-091482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526091482/0001193125-26-091482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526091482/sght-20260304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:40:41.967233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95f64cc4eabd0ab51b4be6324182963937e0ac15","claim":"Sight Sciences, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $20.4 million, net income $4.2 million, EPS $0.08 per share. Guidance initiated.","evidence_excerpt":"quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026. Recent Financial Highlights • Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2024. • Achieved total","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526091482/0001193125-26-091482-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$20.4 million"},{"label":"Net income","value":"$4.2 million"},{"label":"EPS","value":"$0.08 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}